Protein kinase C and oxidative stress in an animal model of mania

Current Neurovascular Research

Volumn 9, Issue 1, 2012, Pages 47-57

  Steckert, Amanda Valnier ^a   Valvassori, Samira Silva ^a   Mina, Francielle ^a   Lopes Borges, Jéssica ^a   Varela, Roger Bitencourt ^a   Kapczinski, Flávio ^b   Dal Pizzol, Felipe ^a   Quevedo, João ^a  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Amphetamine; Animal model of mania; Bipolar disorders; Oxidative stress; Protein kinase c; Tamoxifen

Indexed keywords

AMPHETAMINE; CARBONYL DERIVATIVE; CATALASE; PROTEIN KINASE C; SUPEROXIDE; SUPEROXIDE DISMUTASE; TAMOXIFEN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; EXPLORATORY BEHAVIOR; HIGH RISK BEHAVIOR; HIPPOCAMPUS; HYPERACTIVITY; LOCOMOTION; MALE; MANIA; MITOCHONDRION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

EID: 84858182787     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720212799297056     Document Type: Article

References (69)

1. Belmaker RH. Bipolar disorders. N Engl J Med 2004; 351:476-86.
2. Kupfer DJ. The increasing medical burden in bipolar disorder. J Am Med Assoc 2005; 293:2528-30. (Pubitemid 40705735)
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. Keck PE Jr. The management of acute mania. BMJ 2003; 327:1002-3.
5. Evins AE, Demopulos C, Nierenberg A, et al. A double-blind, placebo-controlled trial of adjunctive donepezil in treatmentresistant mania. Bipolar Disord 2006; 8:75-80. (Pubitemid 43356023)
6. Zarate CA, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9:561-70. (Pubitemid 47365623)
7. Friedman E, Hoau Yan W, Levinson D, et al. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry 1993; 33:520-5. (Pubitemid 23167218)
8. Tanaka C, Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci 1994; 17:551-67. (Pubitemid 24117042)
9. Casabona G. Intracellular signal modulation: a pivotal role for protein kinase C. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:407-25. (Pubitemid 27246002)
10. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59:1006-1020. (Pubitemid 43849653)
11. Goodwin FK, Jamison KR. Manic Depressive Illness, ed 1. New York, Oxford University
12. Hahn CG, Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1990; 1:81-6.
13. Iwata SI, Hewlett GH, Ferrell ST, et al. Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J Pharmacol Exp Ther 1997; 283:1445-52. (Pubitemid 28016520)
14. Giambalvo CT. Protein kinase C and dopamine transport. 2. Effects of amphetamine in vitro. Neuropharmacology 1992; 31:1211-22. (Pubitemid 23002104)
15. Gnegy ME, Hong P, Ferrell ST. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 1993; 20:289-98.
16. Chen G, Manji HK, Hawver DB, et al. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994; 63:2361-4.
17. Browman KE, Kantor L, Richardson S, et al. Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies. Brain Res 1998; 814:112-9. (Pubitemid 29023416)
18. Young LT, Wang JF, Woods CM, et al. Platelet protein kinase C alpha levels in drug-free and lithium treated subjects with bipolar disorder. Neuropsychobiology 1999; 40:63-6. (Pubitemid 29410821)
19. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994; 31:41-52. (Pubitemid 24264211)
20. Horgan K, Cooke E, Hallett MB, et al. Inhibition of protein kinase C-mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 1986; 35:4463-5. (Pubitemid 17223279)
21. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32:485-9.
22. Einat H, Yuan PX, Szabo ST, et al. Protein kinase C inhibition antagonizes several facets of manic-like behaviors: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; 55:123-31. (Pubitemid 47525230)
23. Bebchuk JM, Arfken CL, Dolan-Manji S, et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57:95-7.
24. Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31:543-7. (Pubitemid 43375956)
25. Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebocontrolled trial of tamoxifen. Arch Gen Psychiatry 2008; 65:255-63. (Pubitemid 351342442)
26. Kuloglu M, Ustundag B, Atmaca M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002; 20:171-5.
27. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003; 121:109-22. (Pubitemid 37500981)
28. Ozcan ME, Gulec M, Ozerol E, et al. Antioxidant enzyme activities and oxidative stress in affective disordes. Int Clin Psychopharmacol 2004; 19:89-95. (Pubitemid 38316767)
29. Savas HA, Gergerlioglu HS, Armutcu F, et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006; 7:51-5. (Pubitemid 43878527)
30. Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008; 107:89-94. (Pubitemid 351288914)
31. Cochrane CG. Mechanisms of oxidant injury of cells. Mol Aspects Med 1991; 12:137-47.
32. De Vasconcelos AP, Bouilleret V, Riban V, et al. Role of nitric oxide in cerebral blood flow changes during kainite seizures in mice: genetic and pharmacological approaches. Neurobiol Dis 2005; 18:270-81. (Pubitemid 40431110)
33. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97:1634-58. (Pubitemid 43873658)
34. Yumru M, Savas H, Kalenderoglu A, et al. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1070-4.
35. Steckert AV, Valvassori SS, Moretti M, et al. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 2010; 35:1295-301.
36. Ericson E, Samuelsson J, Ahlenius S. Photocell measurements of rat motor activity. A contribution to sensitivity and variation in behavioral observations. J. Pharmacol Methods 1991; 25:111-22.
37. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003; 463:3-33. (Pubitemid 36205070)
38. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J 1972; 128:617-27.
39. Boveris A. Determination of the production of superoxide radicals and hydrogen peroxide in mitochondria. Methods Enzymol 1984; 105:429-35. (Pubitemid 14165408)
40. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186:421-31. (Pubitemid 20279983)
41. Levine RL, Williams JA, Stadtman ER, et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233:346-57.
42. Bannister JV, Calabrese L. Assays for superoxide dismutase. Methods Biochem Anal 1987; 32:279-312.
43. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105:121-6.
44. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-7.
45. Robinson PJ. The role of protein kinase C and its neuronal substrates dephosphin, B- 50, and MARCKS in neurotransmitter release. Mol Neurobiol 1991; 5:87-130.
46. Cowell RM, Kantor L, Hewlett GH, et al. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol 2000; 389:59-65. (Pubitemid 30109367)
47. Kantor L, Gnegy ME. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 1998; 284:592-8. (Pubitemid 28086646)
48. Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2010; 129:327-31.
49. Sabioni P, Baretta IP, Ninomiya EM, et al. The antimanic-like effect of tamoxifen: Behavioural comparison with other PKCinhibiting and antiestrogenic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1927-31.
50. Frey BN, Valvassori SS, Réus GZ, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006; 31:326-32. (Pubitemid 44497429)
51. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111:135-44.
52. Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1677-81.
53. Musavi S, Kakkar P. Diazepam induced early oxidative changes at the subcellular level in rat brain. Mol Cell Biochem 1998; 78:41-6. (Pubitemid 28121739)
54. Musavi S, Kakkar P. Pro and antioxidant responses to repeated administration of diazepam in rat brain. Mol Cell Biochem 2000; 206:97-103. (Pubitemid 30246511)
55. Musavi S, Kakkar P. Effect of diazepam treatment and its withdrawal on pro/antioxidative processes in rat brain. Mol Cell Biochem 2003; 245:51-6. (Pubitemid 36416821)
56. Kimelberg H, Feurstel P, Jin Y, et al. Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport 2000; 11:2675-9.
57. Cardoso CM, Almeida LM, Custodio JB. 4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition. Mitochondrion 2002; 1:485-95.
58. Cardoso CM, Almeida LM, Custodio JB. Protection of tamoxifen against oxidation of mitochondrial thiols and NAD(P)H underlying the permeability transition induced by prooxidants. Chem Biol Interact 2004; 148:149-61. (Pubitemid 38987832)
59. Obata T. Tamoxifen protect against hydroxyl radical generation induced by phenelzine in rat striatum. Toxicology 2006; 222:46-52.
60. Zhao Y, Wang LM, Chaiswing L, et al. Tamoxifen protects against acute tumor necrosis factor --induced cardiac injury via improving mitochondrial functions. Free Radic Biol Med 2006; 40:1234-41.
61. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4 methylenedioxymethamphetamine administration. Eur J Pharmacol 2000; 398:11-8. (Pubitemid 30336672)
62. Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Neurotox Res 2005; 8:199-206.
63. Deng X, Cai NS, McCoy MT, et al. Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 2002; 42:837-45. (Pubitemid 34518283)
64. Valvassori SS, Rezin GT, Ferreira CL, et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 2010; 44:903-9.
65. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein Kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46:1328-51.
66. Nazarewicz RR, Zenebe WJ, Parihar A, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007; 67:1282-90.
67. Li HC, Chen QZ, Ma Y, et al. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci 2006; 7:1981-6.
68. Benes FM, Matzilevich D, Burke RE, et al. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 2006; 11:241-51.
69. Herken H, Uz E, Ozyurt H, et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73. (Pubitemid 32096067)